Clinical trialNCT02267603CompletedPhase 2Interventional

Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer

SponsorNational Cancer Institute (NCI)Enrollment50Recurrent Merkel Cell CarcinomaStage III Merkel Cell Carcinoma AJCC v7Stage IIIA Merkel Cell Carcinoma AJCC v7Stage IIIB Merkel Cell Carcinoma AJCC v7Stage IV Merkel Cell Carcinoma AJCC v7

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase II trial studies how well pembrolizumab works in treating patients with Merkel cell cancer that cannot be removed by surgery or controlled with treatment, or has spread to other parts of the body. Pembrolizumab may stimulate the immune system to identify and destroy cancer cells.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Paul Nghiem
Cancer Immunotherapy Trials Network
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Stanford Cancer Institute Palo Alto
Palo Alto, California, United States
Ucsf Medical Center-Mount Zion
San Francisco, California, United States
Yale University
New Haven, Connecticut, United States
Moffitt Cancer Center
Tampa, Florida, United States
Emory University Hospital/winship Cancer Institute
Atlanta, Georgia, United States
Louisiana State University Health Science Center
New Orleans, Louisiana, United States
University Medical Center New Orleans
New Orleans, Louisiana, United States
Johns Hopkins University/sidney Kimmel Cancer Center
Baltimore, Maryland, United States
Mount Sinai Hospital
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
University of Pittsburgh Cancer Institute (upci)
Pittsburgh, Pennsylvania, United States
Seattle Cancer Care Alliance
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Pembrolizumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 25 Nov 2014
Primary completion: 6 Feb 2018
Completion: 15 Dec 2021
Last update posted: 5 Jul 2023
Registered enrollment: 50
Registry id: NCT02267603

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.